Immunic, inc. announces fda clearance to begin imu-838 phase 3 ensure studies in relapsing-remitting multiple sclerosis and phase 2 calliper study in progressive multiple sclerosis

New york, july 1, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced u.s. food and drug administration (fda) clearance of its investigational new drug (ind) application for the phase 3 ensure program of lead asset imu-838, the company's selective oral dhodh inhibitor, in patients with relapsing-remitting multiple sclerosis (rrms). in addition, the fda also cleared the company's separate ind application for the supportive phase 2 calliper trial of imu-838 in patients with progressive multiple sclerosis (pms).
IMUX Ratings Summary
IMUX Quant Ranking